Drug Trial Radar · NCT05818943
Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder
Last checked: Nov 19, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Mar 7, 2023
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- GRIN Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A. After the end of part A, all participants who are still eligible can choose to continue to receive radiprodil as part of an open-label long-term treatment period (Part B).
Conditions
- GRIN-related Disorders
Interventions
RadiprodilDrug
Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), TEAEs Leading to Discontinuation and Severity of TEAEsTime frame: through study completion (average of 2 years).
- Maximum Plasma concentration of radiprodil (Cmax)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
- Pharmacokinetic plasma concentration of radiprodil: half-life (T1/2)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
- Plasma concentration of radiprodil versus time, area under the curve (AUCt)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
- Pharmacokinetic plasma concentration of radiprodil, clearance (Cl)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
- Pharmacokinetic plasma concentration of radiprodil, Time corresponding to occurrence of Cmax (Tmax)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
Locations
15 sites in 8 countries. Site status is shown where the registry gives one.
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Columbia University Irving Medical Center, Dept of Neurology
New York, New York
Queensland Children's Hospital
South Brisbane, Queensland, Australia
BC Children's Hospital
Vancouver, Canada
The Hospital for Sick Children (Sick Kids)
Toronto, Ontario, Canada
Abteilung für Neuropädiatrie, Klinik und Poliklinik für Kinder - und Jugendmedizin, Universitätsklinikum Leipzig
Leipzig, Germany
KBO-Kinderzentrum München gemeinnützige GmbH
München, Germany
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu
Rome, Lazio, Italy
Azienda Ospedaliero Universitaria Careggi (AOUC) Firenze - Azienda Ospedaliera Universitaria Meyer
Florence, Tuscany, Italy
ERASMUS Medisch Centrum, Developmental & Genetic pediatrics
Rotterdam, Netherlands
UMC Utrecht - Wilhelmina Kinderziekenhuis, Polikliniek Kinderneurologie
Utrecht, Netherlands
Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB)
Barcelona, Spain
Hospital Ruber Internacional
Madrid, Spain
Royal Hospital for Children Glasgow
Glasgow, United Kingdom
Great Ormond Street Hospital For Children NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.